2024-516611-24-00撤回1 期
A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 18
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
AstraZeneca Clinical Study Information Center
Scientific
AstraZeneca AB
研究点 (3)
Loading locations...
相似试验
招募中
2 期
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT2023-504925-38-00GBG Forschungs GmbH176
招募中
1 期
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLLymphomaLeukemiaNCT07294677University of Chicago104
已完成
2 期
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease2024-512756-38-00Boehringer Ingelheim International GmbH27
招募中
3 期
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2− Breast Cancer (CAPItello-291)2023-505042-25-00AstraZeneca AB366
尚未招募
2 期
Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).Liver Transplant ComplicationsNCT07305363University of California, San Diego10